Mutations in variable domains of the HIV-1 envelope gene can have a significant impact on maraviroc and vicriviroc resistance by unknown
Asin-Milan et al. AIDS Research and Therapy 2013, 10:15
http://www.aidsrestherapy.com/content/10/1/15RESEARCH Open AccessMutations in variable domains of the HIV-1
envelope gene can have a significant impact on
maraviroc and vicriviroc resistance
Odalis Asin-Milan1,2, Annie Chamberland1,2, Yi Wei1, Alpha Haidara1,2, Mohamed Sylla1,2
and Cécile L Tremblay1,2,3,4*Abstract
Background: Resistance to CCR5 inhibitors, such as maraviroc and vicriviroc is characterized by reduction of
maximal percent inhibition which indicates the use of an inhibitor-bound conformation of CCR5 for human
immunodeficiency virus-1(HIV-1) entry. It is accompanied by substitutions in gp120 and gp41. Variable domain 3
(V3) plays the most important role, but substitutions outside V3 could also be involved in phenotype resistance. In
this work, we investigated how mutations in variable regions of the viral envelope protein gp120 can contribute to
CCR5 inhibitor resistance.
Methods: Resistant isolates were selected by passaging CC1/85 and BaL viruses with sub-inhibitory MVC and VCV
concentrations. Mutations in gp160 were identified and mutants containing V2 (V169M), V3 (L317W) and V4 (I408T)
were constructed.
Results: MVC and VCV susceptibility and viral tropism were assessed by single cycle assay. Mutant I408T showed
4-fold change (FC) increase in the half maximal inhibitory concentration (IC50) to MVC, followed by L317W (1.52-FC),
V169M (1.23-FC), V169M/I408T (4-FC) L317W/I408T (3-FC), V169M/L317W (1.30-FC), and V169M/L317W/I408T
(3.31-FC). MPI reduction was observed for mutants I408T (85%), L317W (95%), V169M/I408T (84%), L317W/I408T
(85%) and V169M/L317W/I408T (83%). For VCV, I408T increased the IC50 by 2-FC and few mutants showed MPI
reduction less than 95%: I408T (94%), L317W/I408T (94%) and V169M/L317W/I408T (94%). All mutants remained
R5-tropic and presented decreased infectivity.
Conclusions: These results suggest that mutations in the V4 loop of HIV-1 may contribute to MVC and VCV
resistance alone or combined with mutations in V2 and V3 loops.
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HIV-1 entry into target cells is initiated by interactions
between the viral envelope (Env) protein gp120 and
the host cell receptor CD4. It triggers conformational
changes in gp120, forming the co-receptor binding site
[1-3]. gp120 interaction with C-C chemokine receptor
5 (CCR5) or C-X-C chemokine receptor 4 (CXCR4)
induces other conformational changes in gp120, which* Correspondence: c.tremblay@umontreal.ca
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distribution, and reproduction in any mediumevoke structural re-arrangement of gp41 and enables
the viral and cellular membrane fusion, permitting viral
entry [4]. CCR5 inhibitors, including maraviroc (MVC),
vicriviroc (VCV), aplaviroc, TAK-779 and TAK-220, an-
tagonize this process and have strong anti-viral activity
against HIV-1 in vitro [5,6]. Although they bind the
hydrophobic pocket within transmembrane domains of
CCR5 with high affinity, they occupy different sub-
cavities by interacting with different amino acids [6].
MVC is the first CCR5 inhibitor approved for the treat-
ment of R5-tropic HIV-1 infection in both naïve and
treatment-experienced adult patients. VCV development
was stopped because of suboptimal efficacy [5]. Sincetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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resistance to these drugs is evidenced by reduction in
the plateau of virus inhibition curves rather than by
increases in 50 percent inhibitory concentration (IC50)
[7,8]. The magnitude of this decrease can be expressed
as maximum plateau inhibition (MPI) [9]. Plateau height
depends on the relative affinity of HIV-1 for inhibitor-
bound versus free CCR5, the greater the affinity for
inhibitor-bound CCR5, the lower the height of the
plateau [7]. MOTIVATE clinical trials of MVC revealed
that the MPI of most MVC-resistant viruses in subjects
failing therapy ranged from 80 to 95% [9]. In VICTOR-E1
clinical trials of VCV, phenotypic resistance was mani-
fested by reductions in relative MPI. The cut-off value was
0.94 [8]. Changes in susceptibility to CCR5 inhibitors are
usually accompanied by substitutions in gp120, with V3
domain appearing to play a critical role. However, substi-
tutions outside this region also contribute to the resistance
phenotype [10]. The aim of this study is to investigate
how mutations in other variable loops of the HIV-1 Env
can contribute to MVC and VCV resistance.
Results
Selection of resistance mutations by in vitro passage
After 4 passages of CC1/85 virus in the presence of
sub-inhibitory MVC concentrations, some mutations,
such as V169M and N192K in V2, L317W in V3, I408A
in V4, D462N, N463T, S464T and N465aD in V5, and
L820I, I829V and Y837C in gp41,were associated with
increased p24 levels (Table 1). After 16 passages, 2 new
mutations materialized: I408T in V4 and P849Q in gp41
(Table 1). It is noteworthy that the mutation I408A in
V4 appeared after 4 passages and disappeared at passage
16, when a new mutation, I408T, surfaced at the same
position.. For VCV, 2 mutations emerged after 4 pas-
sages: V169M in V2 and L317W in V3. After 16 pas-
sages, the mutation I840Y arose in gp41. No amino
acid change was observed with either drug in the Env
region of laboratory-adapted BaL virus after 16 pas-
sages (Additional file 1).
Susceptibility of mutant clones to MVC and VCV
Significant (85%) reduction in MVC's MPI was apparent
for I408T, 84% for the double mutant V169M/I408T,
85% for L317W/I408T, and 83% for the triple mutant
V169M/L317W/I408T. L317W and V169M/L317W mu-
tants presented intermediate resistance of 95% and 94%,
respectively. No significant MPI diminution occurred for
the single mutant V169M (96%). A similar pattern was
observed when measuring fold-change (FC) increase in
the IC50, with I408T showing 4-FC, L317W 1.52-FC,
and V169M, 1.23-FC increase. The double mutants
V169M/L317W exhibited 1.30-FC, V169M/I408T 4-FC
and L317W/I408T 3-FC, and 3.31-FC was evident forthe triple mutant V169M/L317W/I408T (Table 2 and
Figure 1A). The single mutants V169M and L317W and
the double mutants V169M/L317W and V169M/I408T
retained their susceptibility to VCV, reaching 100% in-
hibition in some cases. For VCV, I408T increased the
IC50 by 2-FC, and the mutants I408T, L317W/I408T
and V169M/L317W/I408T showed MPI of 94%, 93%
and 94%, respectively (Table 3 and Figure 1B).
Mutations affect virus infectivity differentially
The CC1/85 parental clone and mutants exhibited diffe-
rent levels of infectivity. All mutants manifested decreased
infectivity that ranged from 20 to 38%. Infectivity percent-
age was 75% for V169M, 76% for L317W, 80% for I408T,
76% for the double mutants V169M/L317W, 63% for
V169M/I408T, 67% for L317W/I408T, and 67% for the
triple mutant V169M/L317W/I408T (Figure 2).
Tropism and V3 net charge
All CC1/85-derived mutants remained R5-tropic. None
of them was able to replicate in U87CD4CXCR4+ cells,
but did so well in U87CD4CCR5+ cells (Tables 2 and 3).
R5-tropism was also confirmed by 2 different genoty-
pic predictors, PSSMX4R5 [11,12] and geno2pheno co-
receptor [13]. No change in V3 net charge was observed.
Discussion
Our findings indicate that viruses resistant to MVC can
retain the use of CCR5 coreceptor as reported previously
[14-16]. CCR5 inhibitors are associated with mutations
in the Env V3 region of R5 isolates [14,17]. Our passage
experiments revealed only 1 polymorphism in the V3
loop crown, L317W, which was associated with reduced
infectivity, but not with resistance to CCR5 inhibitors or
changes in V3 net charge (Tables 1 and 2). The selection
of HIV-1 resistance to CCR5 inhibitors is relatively diffi-
cult [14,18], the V3 loop being the least variable of the
HIV-1 Env variable regions [19]. Marozsan et al. found
no amino acid changes in the V3 loop of CC1/85 resis-
tant to VCV generated in vitro [15]. Wesby et al. repor-
ted a MVC-resistant CC1/85 virus generated in passage
experiments with only 2 changes in amino acid positions
316 and 323 in the V3 loop [14]. Anastassopoulou et al.
described D1/86.16, a VCV escape mutant that has no
mutations in V3 [20].
Interestingly, when V3 substitution L317W is associ-
ated with V4 substitution I408T or triple substitution
V169M/L317W/I408T, it confers further reduction of in-
fectivity to 70% of the parental clone (Figure 2). This de-
creased infectivity could be due to lower fusion activity
or binding affinity to the CCR5 co-receptor molecule of
the mutant L317W.
The same polymorphism was found by Yu et al. in V3
region of the gp120 isolates CRF07_BC and CRF01_AE,
Table 1 Summary of sequence changes in env gene associated with decreased susceptibility to MVC and VCV in
passages experiments
Virus, drug Passage no. gp 120 V2 loop amino acid sequence
CC1/85 start 158 198
SFNITTSIRNKVQKQYALFYKLDVVPIDNDSNNTNYRLISC
CC1/85 control 4 ------------------------------------------------------------------------
CC1/85, maraviroc 4 --------------------M--------------------------------------------K-------
CC1/85, vicriviroc 4 --------------------M------------------------------------------------------
CC1/85 control 16 -----------------------------------------------------------------------------
CC1/85, maraviroc 16 --------------------M--------------------------------------------K-------
CC1/85, vicriviroc 16 --------------------M------------------------------------------------------
gp 120 V3 loop amino acid sequence
CC1/85 start 296 331
CTRPNNYTRKSIHIGPGRALYATGDIIGDIRQAHC
CC1/85 control 4 -----------------------------------------------------------------
CC1/85, maraviroc 4 -----------------------------------W--------------------------
CC1/85, vicriviroc 4 -----------------------------------W--------------------------
CC1/85 control 16 -----------------------------------------------------------------
CC1/85, maraviroc 16 -----------------------------------W--------------------------
CC1/85, vicriviroc 16 -----------------------------------W---------------------------
gp 120 V4 loop amino acid sequence
CC1/85 start 385 418
CNSTKLFNSTWTWNNSTWNNTKRANDIEEIITLPC
CC1/85 control 4 --------------------------------------------------------------------
CC1/85, maraviroc 4 -----------------------------------------------------A-------------
CC1/85, vicriviroc 4 ---------------------------------------------------------------------
CC1/85 control 16 -----------------------------------------------------A-------------
CC1/85, maraviroc 16 -----------------------------------------------------T--------------
CC1/85, vicriviroc 16 --------------------------------------------------------------------
gp 120 V5 loop amino acid sequence
CC1/85 start 461 469
KDNSTNEIFR
CC1/85 control 4 -----------------
CC1/85, maraviroc 4 TN--T----N---
CC1/85, vicriviroc 4 -------------------
CC1/85 control 16 ---------------
CC1/85, maraviroc 16 TNTT-D----
CC1/85, vicriviroc 16 -------------
gp 41 amino acid sequence
CC1/85 start 642 681
IYNLLEESQNQQEKNEQELLELDKWANLWNWFDISNWLWY
CC1/85 control 4 ---------------------------------------------------------------------------------
CC1/85, maraviroc 4 --------------------------------------------------------------------------------
CC1/85, vicriviroc 4 --------------------------------------------------------------------------------
CC1/85 control 16 ---------------------------------------A--------------------------------------
CC1/85, maraviroc 16 ---------------------------------------A--------------------------------------
CC1/85, vicriviroc 16 --------------------------------------------------------------------------------
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Table 1 Summary of sequence changes in env gene associated with decreased susceptibility to MVC and VCV in
passages experiments (Continued)
gp 41 amino acid sequence
CC1/85 start 812 850
IKIFINATALAVAEGTDRILEVLQRAYRAILHIPRRIRP
CC1/85 control 4 -----------------I-----------------------------------------------------
CC1/85, maraviroc 4 -----------------I-----------------V-----------C--------------------
CC1/85, vicriviroc 4 ------------------------------------------------------------------------
CC1/85 control 16 -----------------I-----------------V----A-----C---------------------
CC1/85, maraviroc 16 -----------------I-----------------V-----------C-------------------Q
CC1/85, vicriviroc 16 ------------------------------------------A----------Y---------------
Residues are numbered according to the HXB2 gp120 sequence.
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naïve to CCR5 inhibitors. In their study, R5 isolates har-
boring 2 dominant polymorphisms, R315Q and F317W
in V3, were less susceptible than B isolates to MVC and
TAK779. They postulated that baseline resistance toFigure 1 Sensitivity of parental and mutant clones to MVC (A)
and VCV (B). HIV-1 Env pseudoviruses bearing the parental clone or
Env-selected mutations V2 (V169M), V3 (L317W) and V4 (I408T) in
single, double and triple combinations served to infect U87-CD4-CCR5
cells in the presence of increasing MVC and VCV concentrations.
Infectivity was assessed by measuring luciferase activity 3 days after
infection. The GraphPad Prism program generated inhibition curves.
In each graph, the percentages of inhibition of parental clones are
shown in red, and all results are the means of 3 experiments, each
performed in triplicate.entry inhibitors may be associated with naturally-
occurring polymorphisms [21]. Yuan et al. [22] studied a
combination of polymorphisms in the gp120 V3 loop of
HIV-1JR-FL virus that can confer non-competitive resis-
tance to MVC with a V3 loop library containing a set of
random combinations of 0-10 polymorphic mutations
in vitro. After 17 passages, they found pseudoviruses
containing the polymorphism F317W (F312W from the
V3 library) with typical non-competitive resistance to
MVC. The polymorphism F317W was also found by
Muñoz-Nieto et al. in 2008 in the env region from pri-
mary isolates during follow-up of dual natural infection
with subtypes B and G [23].
In our study, I408T in V4 was the mutation that
conferred the highest level of resistance. This mutationTable 2 Susceptibility and phenotypic properties of V2,
V3 and V4 single, double and triple mutants against
maraviroc
Loop Mutant Tropism IC50 IC50 MPI
FC increase
Parental clone Wild type R5 1.47 nM - -
V2 V169M R5 1.82 nM 1.23 96%
V3 L317W R5 2.24 nM 1.52 95%
V4 I408T R5 5.46 nM 4.00 85%
V2-V3 V169M R5 1.92 nM 1.30 94.3%
L317W
V2-V4 V169M R5 5.76 nM 4.00 84%
I408T
V3-V4 L317W R5 4.29 nM 3.00 85%
I408T
V2-V3-V4 V169M R5 4.88 nM 3.31 83%
L317W
I408T
IC50, 50% effective concentration or concentration needed to inhibit 50% of HIV.
IC50 FC was calculated as the ratio IC50 for resistant virus/IC50 for wild type virus.
MPI (maximum percent inhibition) was calculated as described in Methods.
Table 3 Summary of susceptibility and phenotypic
properties of V2, V3 and V4 single, double and triple
mutants against vicriviroc
Loop Mutant Tropism IC50 IC50 MPI
FC increase
Parental clone Wild type R5 1.56 nM - -
V2 V169M R5 1.61 nM 1.03 100%
V3 L317W R5 1.90 nM 1.21 100%
V4 I408T R5 3.16 nM 2.02 94%
V2-V3 V169M R5 1.56 nM 1.57 100%
L317W
V2-V4 V169M R5 1.62 nM 1.03 96%
I408T
V3-V4 L317W R5 1.68 nM 1.07 93%
I408T
V2-V3-V4 V169M R5 1.59 nM 1.01 94%
L317W
I408T
IC50, 50% effective concentration or concentration needed to inhibit 50% of HIV.
IC50 FC was calculated as the ratio IC50 for resistant virus/IC50 for wild type virus.
MPI (maximum percent inhibition) was calculated as described in Methods.
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experiments. It was a change from medium size and
hydrophobic I to medium size and polar T. The muta-
tion conferred resistance to MVC and was linked with
cross-resistance to VCV, as indicated by MPI values. Al-
though cross-resistance was observed for VCV, the virusFigure 2 Effect of Env glycoprotein mutations on infectivity of the HI
Env pseudoviruses bearing parental clone (wild type) or Env single mutant
L317W/I408T and the triple mutant V169M/L317W/I408T. Means from 3 inde
infectivity was calculated as RLU of the mutant/RLU of the wild type × 100%was more resistant to MVC. Cross-resistance is com-
monly seen among CCR5 inhibitors [5]. Even if VCV
had a favorable resistance profile, its virological activity
was sub-optimal in phase II and III studies, possibly
because of its pharmacokinetic profile and the dose
chosen [5,24]. Tilton et al. [25] analyzed viruses from 11
treatment-experienced patients in whom virologic failure
occurred on regimens containing MVC and noted that
resistance was dependent upon mutations within the V3
loop which was only modulated by additional mutations
in the V4 loop. The V4 mutations consisted of D407G
and loss of a glycosylation site at residue 386.
Platt et al. [26] described HIV-1 CCR5 (ΔNt)-adapted
mutants of the JR-CSF strain that had mutations in
regions V3, V2 and C3 with 4 mutations in the V4 loop:
N403S, N403K, T405A, and T405N. They concluded
that loss of N-glycan at position 403 helps to convert
the HIV-1 env into a hairpin-trigger form that no longer
requires strong interactions with both the CCR5 ami-
no terminus and ECL2 but efficiently targets either site
alone [27-32]. Based on these models, we could postu-
late that the presence of T in position 408 of the V4 loop
could alter the quaternary structure of the gp120-gp41
trimeric complex, eliciting conformational transition from
a high-energy to a low-energy state (fusogenic confor-
mation), enhancing membrane fusion, and promoting the
next step in the virus entry pathway. Since positions 403
and 408 of the V4 loop are close proximity, we imagine
that the resistance conferred by I408T mutation in our
study could alter the quaternary structure of the HIV-1V-1 strain CC1/85. U87-CD4-CCR5 cells were infected with HIV-1
s V169M, L317W, I408T, double mutants V169M/L317W, V169M/I408T,
pendent experiments performed in triplicate are reported. Pseudovirus
.
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position 403.
Mutations in V2, C3 and gp41 have also been ob-
served in CC1/85-derived, MVC-resistant viruses [14].
The mutation V169M, identified in our study, was also
found by Marozsan et al. in VCV escape mutant, which
was resistant to VCV, but they did not investigate the
contribution of each individual mutation to the resistant
phenotype [15]. Recently, Thielen et al. [33] demon-
strated that mutations at position 169 of the V2 loop can
serve in HIV-1 co-receptor prediction. In their study,
the mutation V169T showed strong association with
CXCR4 usage while V169K was coupled with CCR5
usage. In another study, the mutation V169K in V2 was
predictive of the R5 phenotype [34]. Our results dis-
closed that mutant V169M exploits R5 exclusively as a
co-receptor. V169M mutation was coupled with reduced
infectivity but not with a resistant phenotype. Unexpec-
tedly, our triple mutant was less infective than single
and double mutants as the emergence of mutations
throughout gp120 and gp41 indicated general envelope
gene (env) re-arrangement to compensate for decreased
replicative capacity [35,36].
Conclusions
Several mutations outside the V3 loop were shown to
contribute to CCR5 inhibitor resistance. Our results
showed that I408T, L317W/I408T and V169M/L317W/
I408T mutants had the highest impact on MVC suscep-
tibility, mostly due to I408T in V4. This mutation could
lower the activation energy needed to enable gp41 to
undergo the next conformational changes and acquire a
more stable low-energy state. All mutants retained the
CCR5 co-receptor, supporting the concept that resistant
viruses maintained the ability to use inhibitor-bound
CCR5, depending on co-receptor density on the cellular
surface and the degree of CCR5 co-receptor occupancy
by drugs.
Methods
Compounds, cells and viruses
MVC and VCV were obtained from ViroChem Inc.
Canada, now Vertex Canada Inc., reconstituted in DMSO
100% (Sigma, St. Louis, MO, USA) and diluted in RPMI
1640 culture medium (Sigma). Peripheral blood mono-
nuclear cells (PBMCs) from 3 HIV-negative donors were
isolated by Ficoll-Paque gradient separation (Sigma),
stimulated for 3 days with phytohemagglutinin (Sigma)
at 1 mg/ml and re-suspended at 2 × 106 cells/ml in
RPMI 1640 supplemented with 20% heat-inactivated
fetal calf serum (FCS, Invitrogen, Carlsbad, CA, USA),
50 U/ml penicillin (Invitrogen), 50 μg/ml streptomycin
(Invitrogen)., 2 mM L-glutamine, 10 mM hydroxyethylpi-
perazine N-2 ethanesulfonic acid (HEPES) and 1 μg/mlinterleukin-2 (Hoffmann-La Roche, Nutley, NJ, USA) in
6-well plates (Becton Dickinson, Lincoln Park, N.J USA.).
293T cells were cultured in Dulbecco’s modified Eagle
medium (DMEM) and supplemented with 10% FCS,
100 U/ml penicillin and 0.1 mg of streptomycin/ml
U87CD4CXCR4 and U87CD4CCR5 cells were cul-
tured in DMEM and supplemented with 10% FCS,
100 U/ml of penicillin, 0.1 mg of streptomycin/ml, 1
μg/mL of puromycin (Sigma) and 300 μg of G418
(Invitrogen). All cells were maintained at 37°C and 5%
CO2. Cells and the viruses BaL and CC1/85 (R5 tropic),
III B (X4-tropic) and 85.6 (dual-tropic) were obtained
from the National Institutes of Health.
Generation of HIV-1 mutants resistant to MVC and VCV
by in vitro passage in PBMCs
2 × 106 PBMCs/ml were infected with 3,000 tissue cul-
ture infective doses 50% of BaL and CC1/85 viruses, in a
final volume of 2 ml containing sub-inhibitory concen-
trations of 0.04 nM MVC and 0.02 nM VCV. Every 7
days, the culture supernatant was passaged onto fresh
cells with MVC- and VVC-containing medium, and vi-
rus growth was monitored by enzyme-linked immuno-
sorbent assay (ELISA) to measure supernatant p24 levels
(Perkin-Elmer, Norwalk, CT, USA). MVC and VCV were
added every 4 days at concentrations depending on p24
levels. MVC and VCV control passages were set up in
parallel. Full length sequences of gp120 and gp41 were
obtained for different time points, and mutations from
resistant viruses were identified. Resistance was defined
as MPI <95% or ≥3-FC in IC50. Viral tropism was pre-
dicted according to 11/25 and net charge rules [37] as
well as PSSMX4R5 [11,12] and geno2pheno co-receptor
algorithms [13].
Amplification and sequence analysis of the HIV env gene
from selected time-points
HIV-1 RNA was extracted from culture supernatants
with QIAmp Viral RNA mini-kit (Qiagen, Mississauga,
ON, Canada). Full-length gp160 was amplified with re-
verse transcription -polymerase chain reaction (RT-PCR)
primers (5’ NewFHindIII GGCCAAGCTTATGAGAGT
GACGGAGATCAG and 5’ YW15XhoI GGCCCTCGA
GTTATCCAGTCCCCCCTTTTC), followed by nested
polymerase chain reaction (PCR) with primers (5’
NewFHindIII GGCCAAGCTTATGAGAGTGACGGAG
ATCAG and 5’ YW16XhoI GGCCCTCGAGTTATTTT
GACCACTTGCCAC). PCR products were separated on
1% agarose gel and purified with QIAprep Spin Miniprep
Kit (Qiagen). Sequencing was undertaken at the Génome-
Québec sequencing facilities in a 3730 × l DNA ana-
lyser from Applied Biosystems (McGill University and
the Genome Quebec Innovation Centre, Montreal,
QC, Canada) with Sequencer 4.7 (Gene Code Software
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ClustalW version 1.83 [10]. Nucleotide sequences of
CC1/85 have been deposited in GenBank under acces-
sion numbers JQ924495 (start), JQ924496 (controlP4),
JQ924497 (MVCP4), JQ924498 (VCVP4), JQ924499 (con-
trolP16), JQ92450 (MVCP16), and JQ924501 (VCVP16).
Site-directed mutagenesis
Primers were designed with the Stratagene’s web-based
QuikChange® Primer Design Program [38]. Mutagenesis
procedures were carried out according to an overlapping-
extension PCR-based procedure [39,40].
Cloning and pseudovirus construction
The expression plasmid pcDNA3.1day/V5HisTOPO
(Invitrogen) and Env PCR products of CC1/85, BaL, III
B, 85.6 viruses and selected mutants (V169M in V2,
L317W in V3 and I408T in V4) in single, double and
triple combinations were digested with HindIII and
Xho1 restriction enzymes (Invitrogen), purified and li-
gated with T4 DNA Ligase (Invitrogen). The ligation
product was transformed into E. coli TOP10 competent
cells. Pseudoviruses were produced by co-transfection of
Env expression plasmid and backbone pNL4-3. Luc.E-R-,
as described previously [41,42]. Pseudovirus stocks were
normalized with p24 ELISA prior to testing infectivity.
Assays were performed with 25 ng of p24 per well.
Luciferase assays to determine infectivity and tropism
A luminescence assay using U87CD4CXCR5 and
U87CD4CXCR4 cells was used to measure infectivity
and tropism. On the day prior to infection, 1×106 cells
per well were seeded in 96-well plates. On the day of
infection, MVC and AMD 3100 were added to wells
designated for treatment with an inhibitor and incubated
for 1 h at 37°C prior to infection. 50 μl of norma-
lized pseudovirus stocks were added in each well. The
plates were incubated for 2 days at 37°C with 5% CO2.
The medium was removed, and 100 μl of lysis buffer
(Promega Inc., Madison, WI, USA) was added to each
well for 30 min. Then, 100 μl of luciferase assay reagent
(Promega) was added immediately prior to reading the
plates in a luminometer (Tecan, Morrisville, NC, USA).
Luciferase activity was recorded as relative light units
(RLU). Viral entry was determined as percent reduction
of viral infectivity compared to the controls. All experi-
ments were performed in duplicate. IC50-FC was calcu-
lated as the ratio of IC50 for resistant virus/IC50 for wild
type virus. MPI was calculated as [1- (RLU in the pre-
sence of drug/RLU in the absence of drug)] × 100, and
infectivity as RLU of the mutant/RLU of the wild type ×
100%. Inhibition curves were generated by GraphPad
Prism software (San Diego, CA, USA).Additional file
Additional file 1: The Env region of laboratory-adapted BaL
virus after 16 passages in the presence of sub-inhibitory VCV
concentrations.
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